The Navigation Model of Therapy: Why Awareness Changes Everything
November 16, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Jadenu Sprinkle, Exjade, Jadenu 
Synonyms :
deferasirox 
Class :
Chelators 
Brand Name :
Jadenu Sprinkle, Exjade, Jadenu 
Synonyms :
deferasirox 
Class :
Chelators 
Dosage Forms & Strengths  Â
Tablet oral (Jadenu)Â
90 mgÂ
180 mgÂ
360 mgÂ
Granules oral (Jaden sprinkle)Â
90 mgÂ
180 mgÂ
360 mgÂ
Oral suspension tablet (Exjade)Â
125 mgÂ
250 mgÂ
500 mgÂ
Dosage Forms & Strengths  Â
Tablet oral (Jadenu)Â
90 mgÂ
180 mgÂ
360 mgÂ
Granules oral (Jaden sprinkle)Â
90 mgÂ
180 mgÂ
360 mgÂ
Oral suspension tablet (Exjade)Â
125 mgÂ
250 mgÂ
500 mgÂ
Refer to adult dosing
It may diminish the serum concentration when combined with bile acid sequestrants
rifampin: they may diminish the serum concentration of deferasirox
may increase GI bleeding, ulceration and irritation
may increase GI bleeding, ulceration and irritation
may increase GI bleeding, ulceration and irritation
may increase GI bleeding, ulceration and irritation
may increase GI bleeding, ulceration and irritation
bisphosphonate derivatives increase the toxicity of deferasirox
bisphosphonate derivatives increase the toxicity of deferasirox
bisphosphonate derivatives increase the toxicity of deferasirox
bisphosphonate derivatives increase the toxicity of deferasirox
may decrease the absorption of iron preparations
may decrease the absorption of iron preparations
may decrease the absorption of iron preparations
may decrease the absorption of iron preparations
may decrease the absorption of iron preparations
may have an increasingly adverse effect when combined with deferasirox
may have an increasingly adverse effect when combined with deferasirox
may have an increasingly adverse effect when combined with deferasirox
may have an increasingly adverse effect when combined with deferasirox
may have an increasingly adverse effect when combined with deferasirox
may have an increasingly adverse effect when combined with deferasirox
may have an increasingly adverse effect when combined with deferasirox
may have an increasingly adverse effect when combined with deferasirox
may have an increasingly adverse effect when combined with deferasirox
may have an increasingly adverse effect when combined with deferasirox
It may enhance the effect when combined with beclomethasone, inhaled by immunosuppressive effects
may have an increasingly adverse effect when combined with deferasirox
may have an increasingly adverse effect when combined with deferasirox
may have an increasingly adverse effect when combined with deferasirox
may have an increasingly adverse effect when combined with deferasirox
may have an increasingly adverse effect when combined with deferasirox
It may increase the toxic effect when combined with Bisphosphonate Derivatives
It may increase the toxic effect when combined with Bisphosphonate Derivatives
It may increase the toxic effect when combined with Bisphosphonate Derivatives
It may increase the toxic effect when combined with Bisphosphonate Derivatives
It may increase the toxic effect when combined with Bisphosphonate Derivatives
When deferasirox is used together with norelgestromin, this leads to a rise in norelgestromin’s metabolism
When deferasirox is used together with adenine, this leads to a reduction in the deferasirox's metabolism
deferasirox: it may enhance the toxic effect of Anti-Inflammatory Agents
deferasirox: it may enhance the toxic effect of Anti-Inflammatory Agents
aspirin, chlorpheniramine, and phenylephrine
deferasirox: it may enhance the toxic effect of Anti-Inflammatory Agents
deferasirox: it may enhance the toxic effect of Anti-Inflammatory Agents
deferasirox: it may enhance the toxic effect of Anti-Inflammatory Agents
deferasirox: it may decrease the therapeutic efficacy of etynodiol
deferasirox: it may decrease the metabolism of cerivastatin
it decreases the concentration of CYP3A4 substrates in serum
may diminish the serum concentration of CYP3A4 Substrates
When deferasirox is used together with lomitapide, this leads to an enhancement in lomitapide’s metabolism
When deferasirox is aided by hesperetin, it elevates concentration serum of hesperetin
Actions and Spectrum: Â
deferasirox works by creating iron-based stable complexes that are then expelled from the body. deferasirox creates a compound with iron in a 2:1 ratio, which the body subsequently excretes through faeces and urine. Â
deferasirox’s main area of therapeutic action is the treatment of chronic iron excess. For acute iron toxicity or iron deficient anaemia, it is ineffective.
Frequency Defined Â
>10%Â
Nausea (11-23%)Â
Influenza (11%)Â
Vomiting (10-21%)Â
Rash (8-11%)Â
Cough (14%)Â
Nasopharyngitis (13%)Â
Pharyngolaryngeal pain (11%)Â
Pyrexia (19%)Â
Headache (16%)Â
<1%Â
AnaphylaxisÂ
Cytopenias, including neutropenia, agranulocytosis and thrombocytopenia; leukocytoclastic vasculitisÂ
AngioedemaÂ
Post marketing reportsÂ
Immune system disorders: Hypersensitivity reactions (including anaphylaxis and angioedema)Â
Gastrointestinal disorders: GI perforation and hemorrhageÂ
Endocrine: HypokalemiaÂ
1-10%Â
ALT increased (2-8%)Â
Arthralgia, back pain (6-7%)Â
Rhinitis (6%)Â
Transaminitis (4%)Â
Urticaria (4%)Â
Fatigue (6%)Â
Ear infection (5%)Â
Acute tonsillitis (6%)Â
Respiratory tract infection (10%)Â
Bronchitis (9%)Â
Black Box WarningÂ
Renal and hepatic failure.Â
Contraindication/Caution:Â
It is contraindicated for those with a Hx of medication or component hypersensitivity, and liver/kidney impairment.Â
Pregnancy warnings:    Â
Pregnancy category: N/AÂ
Lactation: Excreted into human milk is unknownÂ
Pregnancy Categories:        Â
Category A: Studies that were well-controlled and met expectations revealed no risk to the fetus in either the first or second trimester.Â
Category B: There were lack of studies on pregnant women and no evidence of risk to the foetus in animal experiments.  Â
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.   Â
Category D: adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.  Â
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.   Â
Category N: There is no data available for the drug under this category
PharmacologyÂ
PharmacodynamicsÂ
It involves interaction with iron ions creating a stable complex that can be eliminated through urine and feces. Its effects can be monitored by measuring serum ferritin levels.Â
PharmacokineticsÂ
Absorption  Â
It is more readily absorbedÂ
DistributionÂ
Protein-bound is dispersed throughout the plasma 99%. Â
MetabolismÂ
It is metabolized deferasirox is glucuronidation.Â
Elimination and excretionÂ
It is excreted by feces (84%) and urine (8%).Â
Administration: Â
It is orally given one daily with/without meals.Â
Patient information leafletÂ
Generic Name: deferasiroxÂ
Why do we use deferasirox?Â
Deferasirox helps in treating sickle cell disease, thalassemia, and chronic anemias due to chronic iron excess caused by frequent blood transfusions which can cause organ damage and malfunction.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
